Dis-Chem Pharmacies Beheer

Beheer criteriumcontroles 4/4

De CEO Dis-Chem Pharmacies is Rui Morais, benoemd in Jul2023, heeft een ambtstermijn van 1.33 jaar. De totale jaarlijkse vergoeding van { bedraagt ZAR 16.70M, bestaande uit 74.8% salaris en 25.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.99% van de aandelen van het bedrijf, ter waarde ZAR 313.72M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 3.8 jaar.

Belangrijke informatie

Rui Morais

Algemeen directeur

R16.7m

Totale compensatie

Percentage CEO-salaris	74.8%
Dienstverband CEO	1.3yrs
Eigendom CEO	1.0%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Shareholders Are Optimistic That Dis-Chem Pharmacies (JSE:DCP) Will Multiply In Value

Nov 10

These 4 Measures Indicate That Dis-Chem Pharmacies (JSE:DCP) Is Using Debt Reasonably Well

Aug 21

Shareholders Should Be Pleased With Dis-Chem Pharmacies Limited's (JSE:DCP) Price

Jun 06

Dis-Chem Pharmacies (JSE:DCP) Will Be Hoping To Turn Its Returns On Capital Around

Apr 17

Dis-Chem Pharmacies (JSE:DCP) Seems To Use Debt Quite Sensibly

Feb 26

Dis-Chem Pharmacies (JSE:DCP) Might Be Having Difficulty Using Its Capital Effectively

Dec 30

If EPS Growth Is Important To You, Dis-Chem Pharmacies (JSE:DCP) Presents An Opportunity

Sep 07

There Are Reasons To Feel Uneasy About Dis-Chem Pharmacies' (JSE:DCP) Returns On Capital

Mar 29

Is Now The Time To Put Dis-Chem Pharmacies (JSE:DCP) On Your Watchlist?

Jan 14

Returns On Capital At Dis-Chem Pharmacies (JSE:DCP) Paint A Concerning Picture

Nov 04

Dis-Chem Pharmacies Limited (JSE:DCP) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 04

We Ran A Stock Scan For Earnings Growth And Dis-Chem Pharmacies (JSE:DCP) Passed With Ease

Sep 01

Some Investors May Be Worried About Dis-Chem Pharmacies' (JSE:DCP) Returns On Capital

Jul 04

A Look At The Fair Value Of Dis-Chem Pharmacies Limited (JSE:DCP)

Jun 21

Dis-Chem Pharmacies (JSE:DCP) Has A Pretty Healthy Balance Sheet

Jun 08

The Dis-Chem Pharmacies Limited (JSE:DCP) Yearly Results Are Out And Analysts Have Published New Forecasts

May 25

Is Dis-Chem Pharmacies (JSE:DCP) A Risky Investment?

Feb 23

Dis-Chem Pharmacies Limited's (JSE:DCP) Price In Tune With Earnings

Feb 08

I Ran A Stock Scan For Earnings Growth And Dis-Chem Pharmacies (JSE:DCP) Passed With Ease

Dec 13

Dis-Chem Pharmacies' (JSE:DCP) Strong Earnings Are Of Good Quality

Nov 09

Analyse CEO-vergoeding

Hoe is Rui Morais's beloning veranderd ten opzichte van Dis-Chem Pharmacies's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Aug 31 2024	n/a	n/a	R1b
May 31 2024	n/a	n/a	R1b
Feb 29 2024	R17m	R12m	R984m
Nov 30 2023	n/a	n/a	R942m
Aug 31 2023	n/a	n/a	R899m
May 31 2023	n/a	n/a	R949m
Feb 28 2023	R18m	R12m	R1b
Nov 30 2022	n/a	n/a	R1b
Aug 31 2022	n/a	n/a	R1b
May 31 2022	n/a	n/a	R946m
Feb 28 2022	R14m	R11m	R853m
Nov 30 2021	n/a	n/a	R815m
Aug 31 2021	n/a	n/a	R776m
May 31 2021	n/a	n/a	R722m
Feb 28 2021	R6m	R6m	R669m
Nov 30 2020	n/a	n/a	R655m
Aug 31 2020	n/a	n/a	R641m
May 31 2020	n/a	n/a	R620m
Feb 29 2020	R6m	R6m	R598m
Nov 30 2019	n/a	n/a	R573m
Aug 31 2019	n/a	n/a	R549m
May 31 2019	n/a	n/a	R634m
Feb 28 2019	R5m	R5m	R719m
Nov 30 2018	n/a	n/a	R718m
Aug 31 2018	n/a	n/a	R718m
May 31 2018	n/a	n/a	R701m
Feb 28 2018	R7m	R5m	R684m

Compensatie versus markt: De totale vergoeding ($USD 923.02K ) Rui } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de ZA markt ($USD 1.35M ).

Compensatie versus inkomsten: De vergoeding van Rui is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Rui Morais (40 yo)

1.3yrs

Tenure

R16,702,000

Compensatie

Mr. Rui Manuel Morais, CA(SA) has been the Chief Executive Officer at Dis-Chem Pharmacies Limited since July 01, 2023 and its Executive Director since August 13, 2012. He served as Chief Financial Officer...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Rui Morais	CEO & Executive Director	1.3yrs	R16.70m	0.99% ZAR 315.5m
J. Pope	CFO & Executive Director	1.3yrs	R5.19m	geen gegevens
Ivan Saltzman	Executive Director	1.4yrs	R18.45m	geen gegevens
Lynette Saltzman	Managing Director	19.5yrs	R14.97m	geen gegevens
Saul Saltzman	Executive Director	2.3yrs	R7.56m	0.79% ZAR 250.3m
Stanley Richard Goetsch	Executive Director	2.3yrs	R7.58m	4.65% ZAR 1.5b
Christopher Williams	Prescribed Officer	no data	R7.81m	geen gegevens
Craig Fairweather	Commercial Director	no data	R15.38m	0.0045% ZAR 1.4m
C. Swanepoel	Prescribed Officer	no data	R4.61m	0.0012% ZAR 372.8k
T. Ponter	Prescribed Officer	no data	R5.11m	geen gegevens
Caryn Barker	Human Resources Director	no data	geen gegevens	geen gegevens
Nikki Lumley	Company Secretary	3.7yrs	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DCP wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Rui Morais	CEO & Executive Director	12.3yrs	R16.70m	0.99% ZAR 315.5m
J. Pope	CFO & Executive Director	1.3yrs	R5.19m	geen gegevens
Ivan Saltzman	Executive Director	19.5yrs	R18.45m	geen gegevens
Saul Saltzman	Executive Director	2.3yrs	R7.56m	0.79% ZAR 250.3m
Stanley Richard Goetsch	Executive Director	2.3yrs	R7.58m	4.65% ZAR 1.5b
Laurence Nestadt	Independent Non-Executive Chairman	8.1yrs	R3.34m	0.058% ZAR 18.6m
Johannes Mthimunye	Independent Non-Executive Director	8.1yrs	R967.00k	0.0095% ZAR 3.0m
Anuschka Coovadia	Independent Non-Executive Director	8.1yrs	R691.00k	0.019% ZAR 6.0m
Alupheli Sithebe	Independent Non-Executive Director	3.8yrs	R750.00k	geen gegevens
Katlego K. Kobue	Non-Independent Non Executive Director	3yrs	R560.00k	geen gegevens
Happy Masondo	Independent Non-Executive Director	2.3yrs	R788.00k	geen gegevens

3.8yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DCP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Dis-Chem Pharmacies Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Insider recently sold R854k worth of stock

Dis-Chem Pharmacies Limited, Annual General Meeting, Jul 31, 2024

Dis-Chem Pharmacies Limited Announces Executive Changes, Effective July 1, 2023

Executive Director exercised options to buy R96k worth of stock.

High number of new directors

Insider recently sold R25m worth of stock

Recent updates

Upcoming dividend of R0.27 per share

Shareholders Are Optimistic That Dis-Chem Pharmacies (JSE:DCP) Will Multiply In Value

First half 2025 earnings released: EPS: R0.67 (vs R0.58 in 1H 2024)

First half dividend increased to R0.27

Dis-Chem Pharmacies Limited to Report Q2, 2025 Results on Oct 25, 2024

These 4 Measures Indicate That Dis-Chem Pharmacies (JSE:DCP) Is Using Debt Reasonably Well

Price target increased by 7.5% to R35.68

Insider recently sold R854k worth of stock

Now 9.7% overvalued after recent price rise

Now 21% overvalued after recent price rise

Upcoming dividend of R0.22 per share

Price target increased by 7.9% to R33.02

Shareholders Should Be Pleased With Dis-Chem Pharmacies Limited's (JSE:DCP) Price

Full year 2024 earnings: EPS misses analyst expectations

First half dividend of R0.22 announced

Now 26% overvalued after recent price rise

Dis-Chem Pharmacies (JSE:DCP) Will Be Hoping To Turn Its Returns On Capital Around

Now 20% overvalued after recent price rise

Dis-Chem Pharmacies (JSE:DCP) Seems To Use Debt Quite Sensibly

Dis-Chem Pharmacies Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Dis-Chem Pharmacies (JSE:DCP) Might Be Having Difficulty Using Its Capital Effectively

Dis-Chem Pharmacies Limited, Annual General Meeting, Jul 31, 2024

Upcoming dividend of R0.23 per share at 1.4% yield

Price target increased by 11% to R27.72

First half 2024 earnings released: EPS: R0.58 (vs R0.70 in 1H 2023)

Dis-Chem Pharmacies Limited(JSE:DCP) dropped from FTSE All-World Index (USD)

If EPS Growth Is Important To You, Dis-Chem Pharmacies (JSE:DCP) Presents An Opportunity

Here's Why Dis-Chem Pharmacies (JSE:DCP) Can Manage Its Debt Responsibly

Dis-Chem Pharmacies (JSE:DCP) Will Want To Turn Around Its Return Trends

Dis-Chem Pharmacies Limited (JSE:DCP) acquired Berea Pharmacy.

Upcoming dividend of R0.18 per share at 1.6% yield

Price target decreased by 7.6% to R27.38

Full year 2023 earnings: EPS misses analyst expectations

Dis-Chem Pharmacies Limited Announces Gross Final Cash Dividend for the Period Ended 28 February 2023, Payable from 12 June 2023

Dis-Chem Pharmacies Limited Announces Executive Changes, Effective July 1, 2023

Is Now The Time To Put Dis-Chem Pharmacies (JSE:DCP) On Your Watchlist?

There Are Reasons To Feel Uneasy About Dis-Chem Pharmacies' (JSE:DCP) Returns On Capital

Price target decreased by 8.5% to R31.10

Price target decreased by 9.6% to R33.00

Dis-Chem Pharmacies Limited to Report Fiscal Year 2023 Results on May 19, 2023

Executive Director exercised options to buy R96k worth of stock.

Is Now The Time To Put Dis-Chem Pharmacies (JSE:DCP) On Your Watchlist?

High number of new directors

Returns On Capital At Dis-Chem Pharmacies (JSE:DCP) Paint A Concerning Picture

Dis-Chem Pharmacies Limited to Report First Half, 2023 Results on Nov 02, 2022

Dis-Chem Pharmacies Limited (JSE:DCP) Shares Could Be 24% Below Their Intrinsic Value Estimate

Now 20% undervalued

We Ran A Stock Scan For Earnings Growth And Dis-Chem Pharmacies (JSE:DCP) Passed With Ease

Insider recently sold R25m worth of stock

Insider recently sold R10m worth of stock

Now 20% undervalued after recent price drop

High number of new directors

Now 20% undervalued after recent price drop

Some Investors May Be Worried About Dis-Chem Pharmacies' (JSE:DCP) Returns On Capital

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

A Look At The Fair Value Of Dis-Chem Pharmacies Limited (JSE:DCP)

Dis-Chem Pharmacies (JSE:DCP) Has A Pretty Healthy Balance Sheet

Upcoming dividend of R0.20 per share

Dis-Chem Pharmacies Limited Declares Final Dividend for the Financial Year 2022

The Dis-Chem Pharmacies Limited (JSE:DCP) Yearly Results Are Out And Analysts Have Published New Forecasts

Dis-Chem Pharmacies Limited Declares Final Dividend for the Financial Year 2022

Full year 2022 earnings: Revenues in line with analyst expectations

Is Dis-Chem Pharmacies (JSE:DCP) A Risky Investment?

Alternate Executive Director recently sold R47m worth of stock

Dis-Chem Pharmacies Limited to Report Fiscal Year 2022 Results on May 23, 2022

Dis-Chem Pharmacies Limited's (JSE:DCP) Price In Tune With Earnings

Insider recently sold R183m worth of stock

High number of new directors

I Ran A Stock Scan For Earnings Growth And Dis-Chem Pharmacies (JSE:DCP) Passed With Ease